Centre for Inflammation Research

Professor Steve Cunningham

Acute respiratory disease in children, particularly in relation to early viral infection, asthma, cystic fibrosis and rare lung disease. Early Phase clinical trials.

Professor Steve Cunningham

Professor of Paediatric Respiratory Medicine

  • Centre for Inflammation Research

Contact details

Background

Consultant in Paediatric Respiratory Medicine at the Children’s hospital in Edinburgh. Trained in Edinburgh, Great Ormond Street and Sydney Children’s Hospital. Currently Vice Chair of the MHRA Paediatric Medicines Expert Advisory Group, Chair of the European Respiratory Society Clinical Research Collaboration.

Research Overview

With an emphasis on early life viral infection, Steve was Chair of the NICE Bronchiolitis guideline and Chief Investigator of BIDS (Bronchiolitis of Infancy Discharge study) investigating oxygen saturation targets in acute viral bronchiolitis (BMJ Clinical Research Paper of the Year 2016). This work continues as PI for the IMI RESCEU study (a pan European RSV study of healthy infants) and within the RESPIRE NIHR Global Centre assessing respiratory disease in children in developing healthcare and as PI and Consultancy for new early phase therapeutic developments for RSV. PaediatrIc PI for the two clinical centre UK Cystic Fibrosis Consortium multidose gene therapy trial, and now focused on the delivery of small molecule therapies in very young children with cystic fibrosis modifying the early disease course. In Asthma, a member of the Asthma UK Centre for Applied Research, assessing near fatal asthma and how best to prevent asthma deaths. In Rare Lung Disease, a core member of the ChILDEU FP7 funded project, which is now followed as Chair of the European Respiratory Society ChILD Clinical Research Collaboration, looking to enhance global collaboration and novel therapeutics for ChILD.

Publications

Smith LJ, Macleod A, Collier GJ, Horn, FC Sheridan H, Aldag I, Taylor CJ, Cunningham S, Wild JM,Horsley A. "upine posture changes lung volumes and increases ventilation heterogeneity in cystic fibrosis. PLoS One 2017, 12(11): e0188275. PMID 29176899 

Griese M, Seidl E, Hengst M, Reu S, Rock H, Anthony G, Kiper N, Emiralioğlu N, Snijders D, Goldbeck L, Leidl R , Ley-Zaporozhan J, Krüger-Stollfuss I, Kammer B, Wesselak T, Eismann C, Schams A, Neuner D, MacLean M, Nicholson AG, Lauren M, lement A, Epaud R, de Blic J, Ashworth M, Aurora P, Calder A, Wetzke M, Kappler M, Cunningham S, Schwerk N, Bush A. International management platform for children's interstitial lung disease (chILD-EU)."Thorax 2017. (In press) PMID: 29056600 

Davies JC, Cunningham S, Harris WT, Lapey A, Regelmann WE, Sawicki GS, Southern KW, Robertson S, Green, Y Cooke J, Rosenfeld M, on behalf of the KIWI Study Group. An Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Patients aged 2 to 5 years with Cystic Fibrosis from a CFTR Gating Mutation: The KIWI Study. Lancet Respiratory Medicine 2016, 4:107-115.    

Cunningham S, Rodriguez A, Adams T, Boyd KA, Butcher I, Enderby B, MacLean M, McCormick J, Paton JY, Wee F, homas H, Riding K, Turner SW, Chris Williams, McIntosh E, Lewis SC, Bronchiolitis of Infancy Discharge Study (BIDS) group. Oxygen saturation targets in acute bronchiolitis (BIDS), a double blind, randomised, equivalence trial. The Lancet 2015, 386:1041-1048. BMJ Awards Clinical Research Paper of the Year 2016.

Alton EW, Armstrong DK, Ashby D, et al, on behalf of the UK Cystic Fibrosis Gene Therapy Consortium. A randomized, double blind, placebo-controlled trial of repeated nebulisaiton of non-viral CFTR gene therapy in patients with cystic fibrosis. Lancet Respiratory Medicine 2015, 3:684-691.